While selective targeting of APC/C or CDK1/2 have yielded limited clinical benefits (due to toxicity)13–15, CDK4/6 inhibitors such as palbociclib have demonstrated remarkable efficacy against several breast cancer subtypes16. The gene discussed is CDK4; the disease is breast cancer.